SCHEMBL31727873

SCHEMBL31727873

Nc1ncnc2c(-c3cccc(Cl)c3Cl)cc(Br)cc12

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SMN1; SMN2 Q16637 1/20 0.40
▸ NUDT1 P36639 5/20 0.40
▸ DGAT1 O75907 1/20 0.39
▸ PIM1 P11309 1/20 0.38
▸ CSNK2A2 P19784 1/20 0.38
▸ CSNK2B P67870 1/20 0.38
▸ PIM3 Q86V86 1/20 0.38
▸ PIM2 Q9P1W9 1/20 0.38
▸ CYP2D6 P10635 1/20 0.38
▸ MAOA P21397 1/20 0.38
▸ MAPK1 P28482 1/20 0.38
▸ ADRA1A P35348 1/20 0.38
▸ SCN4A P35499 1/20 0.38
▸ BLM P54132 1/20 0.38
▸ PMP22 Q01453 1/20 0.38
▸ PDE3A Q14432 1/20 0.38
▸ SCN5A Q14524 1/20 0.38
▸ SCN9A Q15858 1/20 0.38
▸ SCN2A Q99250 1/20 0.38
▸ SCN3A Q9NY46 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31728623 0.87 SMN1; SMN2 (0.39) SMN1; SMN2NUDT1MAP4K4PDE5ALIMK1
SCHEMBL31728633 0.84 MAP4K4 (0.41) NUDT1DGAT1CYP2D6MAOAMAPK1
SCHEMBL31728863 0.81 DGAT1 (0.39) NUDT1DGAT1CYP2D6MAOAMAPK1
SCHEMBL31728376 0.78 MAP4K4 (0.53) MAP4K4LIMK1
SCHEMBL31727998 0.77 MAP4K4 (0.49) DGAT1MAP4K4PTPN11
SCHEMBL31728332 0.76 CLK1 (0.38) MAP4K4PDE5A
SCHEMBL31729125 0.76 DGAT1 (0.38) NUDT1DGAT1CYP2D6MAOAMAPK1
SCHEMBL22715706 0.76 PDE5A (0.44) SMN1; SMN2MAP4K4PDE5ALIMK1
SCHEMBL31728779 0.75 NOTUM (0.43) NUDT1DGAT1
SCHEMBL31729239 0.75 CNR2 (0.53) DGAT1PTPN11

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2025235874-A1 HETEROCYCLICS AS EGFR INHIBITORS SCHRÖDINGER, INC. (US) 2025-11-13 — — WO disclosed
Send feedback